Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.